Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

NACompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 6, 2020

Primary Completion Date

August 26, 2020

Study Completion Date

August 26, 2020

Conditions
Migraine
Interventions
OTHER

11-point pain scale

Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.

OTHER

Headache diary

Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.

DEVICE

Avulux®

Avulux® device

DEVICE

Sham Avulux®

Sham Avulux®

Trial Locations (3)

43201

Endocrinology Research Associates, Inc., Columbus

43215

Remington-Davis Clinical Research, Columbus

55402

Clinical Research Institute, Inc., Minneapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Imarc Research, Inc.

INDUSTRY

lead

Avulux, Inc.

INDUSTRY

NCT04341298 - Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches | Biotech Hunter | Biotech Hunter